Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial-Reference-Cited by-同舟云学术

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Published:2014-06 Issue:7 Volume:15 Page:747-756
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

von Minckwitz Gunter,Schneeweiss Andreas,Loibl Sibylle,Salat Christoph,Denkert Carsten,Rezai Mahdi,Blohmer Jens U,Jackisch Christian,Paepke Stefan,Gerber Bernd,Zahm Dirk M,Kümmel Sherko,Eidtmann Holger,Klare Peter,Huober Jens,Costa Serban,Tesch Hans,Hanusch Claus,Hilfrich Jörn,Khandan Fariba,Fasching Peter A,Sinn Bruno V,Engels Knut,Mehta Keyur,Nekljudova Valentina,Untch Michael

Publisher

Elsevier BV

Subject

Oncology

Reference33 articles.

1. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer;Liedtke;J Clin Oncol,2008

2. Pathological complete response after neoadjuvant chemotherapy + trastuzumab treatment predicts survival and detects a patient subgroup at high need for improvement of anti-HER2 therapy. Three year median follow up data of the TECHNO trial;Untch;J Clin Oncol,2011

3. Definition and impact of pCR on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes;von Minckwitz;J Clin Oncol,2012

4. PCR and accelerated drug approval in early breast cancer;Prowell;N Engl J Med,2012

5. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

Cited by 823 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-generation biomarkers for prognostic and potential therapeutic enhancement in Triple negative breast cancer;Critical Reviews in Oncology/Hematology;2024-09

2. Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer;Current Treatment Options in Oncology;2024-08-15

3. Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer;Scientific Reports;2024-08-05

4. Impact of response to neoadjuvant chemotherapy on surgical modality in patients with T1-2N0-1M0 triple-negative breast cancer;Journal of Cancer Research and Clinical Oncology;2024-08-01

5. Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study;eClinicalMedicine;2024-08